Andreas KRAUSE

City:

Allschwil

Country:

Switzerland

Published Applications:

Last publication date:

2025-09-11

Top Assignees for applications by Andreas KRAUSE

The entities that hold a legal rights for patent applications filed by inventor KRAUSE Andreas:

Actelion Pharmaceuticals Ltd. 5 Allschwil, Switzerland
IDORSIA PHARMACEUTICALS LTD 2 Allschwil, Switzerland
IDORSIA PHARMACEUTICALS LTD 1 , Switzerland
Vanda Pharmaceuticals, Inc. 1 Washington, DC United States

Recent patent applications by KRAUSE Andreas

Andreas KRAUSE from Allschwil, CH has applied for patents for these inventions. The list has both pending applications and granted patents:

#1 | 2025-09-11

US20250281463A1

Human necessities

DOSING REGIMEN FOR A SELECTIVE S1P1 RECEPTOR AGONIST

#2 | 2023-04-27

US20230131600A1

Human necessities

DOSING REGIMEN FOR A SELECTIVE S1P1 RECEPTOR AGONIST

#3 | 2023-01-05

US20230002365A1

Chemistry; metallurgy

Crystalline form of the compound (s)-3-{4-[5-(2-cyclopentyl-6-methoxy-pyridin-4-yl)-[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methyl-phenoxy}-propane-1,2-diol

#4 | 2021-02-25

US20210052555A1

Human necessities

Dosing regimen for a selective S1Preceptor agonist

#5 | 2019-10-24

US20190322657A1

Chemistry; metallurgy

Crystalline form of the compound (S)-3-{4-[5-(2-cyclopentyl-6-methoxy-pyridin-4-yl)-[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methyl-phenoxy}-propane-1,2-diol

#6 | 2019-05-23

US20190151292A1

Human necessities

Dosing regimen for a selective S1Preceptor agonist

#7 | 2018-05-31

US20180147188A9

Human necessities

Dosing regimen for a selective S1Preceptor agonist

#8 | 2017-11-09

US20170319555A1

Human necessities

Dosing regimen for a selective S1Preceptor agonist

#9 | 2006-05-11

US20060099591A1

Chemistry; metallurgy

Diagnosis of chronic rejection

InventorID:

2031146 ⎘